AMRN news & sentiment — AMARIN CORP PLCUK

MAR 18·Stock TitanHigh

Heart drug that cuts heart attack, stroke risk 25% gets guideline boost

Amarin (NASDAQ: AMRN) has welcomed the updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, which endorses icosapent ethyl (IPE) for statin-treated patients with elevated triglycerides to reduce cardiovascular risk. The guideline reinforces that IPE, marketed as VASCEPA/VAZKEPA, reduces cardiovascular events by 25% and supports a broader approach to dyslipidemia management beyond LDL-C lowering. This endorsement is seen as a significant step forward in patient care, addressing residual cardiovascular risk in millions of patients.

NOV 11·GlobeNewswire

RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA ( 1 ) +11.8%, ADJUSTED NET INCOME ( 2 ) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION

NEWS RELEASE ...

NOV 9·GlobeNewswire

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® ( Icosapent Ethyl ) Reduced Cardiovascular Events in High-Risk Patients

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 ( GLOBE NEWSWIRE ) -- Amarin Corporation plc ( NASDAQ: AMRN ) , a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly ...

$AMRN

Heart drug that cuts heart attack, stroke risk 25% gets guideline boost

RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA ( 1 ) +11.8%, ADJUSTED NET INCOME ( 2 ) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® ( Icosapent Ethyl ) Reduced Cardiovascular Events in High-Risk Patients

News on $AMRN